Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TSXPRNBullishIndustry Newsnews

High materiality7/10

Profound to Present TULSA-PRO MRI-Guided Therapy at SRS2026

Jul 15, 2026, 7:48 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

High-visibility events (SRS2026, SIS plenary, investor session) can trigger near-term trading interest, especially with CAPTAIN safety data and real-world outcomes; cross-listing improves accessibility for investors to PRN/PROF; lack of revenue guidance tempers magnitude.

AI summary

What happened, with direct paths to the underlying reporting

Profound Medical will highlight its TULSA-PRO MRI-guided, AI-powered incisionless prostate therapy at SRS2026, including CAPTAIN trial safety outcomes and real-world data. The company is one of eight firms spotlighted in SIS plenary and will participate in an investor session, potentially boosting visibility and near-term demand if data validate advantages over surgical alternatives.

Profound to showcase TULSA-PRO at SRS2026; AI-guided prostate therapy featured.
CAPTAIN trial safety data to be presented July 24, 2026 at UT Southwestern.
Profound spotlighted as one of eight SIS plenary session participants.
Investor session scheduled July 22, 2026, signaling near-term investor engagement.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.